| 摘要 |
PROBLEM TO BE SOLVED: To provide novel methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease.SOLUTION: A method of treating a gastrointestinal inflammatory disorder in a patient comprises administering to the patient a therapeutically effective amount of an integrin beta 7 antagonist, the integrin beta 7 antagonist being administered subcutaneously. The integrin beta 7 antagonist is preferably a monoclonal anti-beta 7 antibody represented by etrolizumab. The anti-beta 7 antibody is preferably administered at a dose of 0.5 mg/kg, or 1.5 mg/kg, or 3.0 mg/kg, or 4.0 mg/kg once every four weeks.SELECTED DRAWING: None |
